Enhancing immune response in melanoma treatment
Targeting dsRNA sensing and ADAR1 in melanoma
['FUNDING_R37'] · YALE UNIVERSITY · NIH-11042275
This study is looking for better ways to help your immune system fight melanoma by targeting certain receptors and blocking a protein that can hold back your body's natural defenses, with the hope of making current treatments work even better for you.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11042275 on ClinicalTrials.gov |
What this research studies
This research investigates ways to improve the effectiveness of melanoma treatments by enhancing the body's immune response. It focuses on targeting specific receptors that recognize double-stranded RNA (dsRNA) and inhibiting a protein called ADAR1, which can limit anti-cancer immunity. By using these strategies, the researchers aim to make melanoma tumors more responsive to existing immunotherapies, potentially leading to better outcomes for patients. The study will explore the best combinations of these approaches to maximize their effectiveness in treating melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma who have not responded well to current immunotherapy treatments.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in enhancing anti-tumor immunity through similar approaches, indicating potential for success in this study.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ISHIZUKA, JEFFREY J. — YALE UNIVERSITY
- Study coordinator: ISHIZUKA, JEFFREY J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer